Secondary chemotherapy for high-risk gestational trophoblastic neoplasia (Q36111446)

12 August 2017

1 reference

title

Secondary chemotherapy for high-risk gestational trophoblastic neoplasia (English)

1 reference

12 August 2017

1 reference

John R Lurain

1

1 reference

12 August 2017

Bahareh Nejad

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

97

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

618-623

1 reference

Treatment of gestational trophoblastic tumors

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Risk factors for the prediction of treatment failure in gestational trophoblastic tumors treated with EMA/CO regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastati

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Treatment of high-risk gestational trophoblastic disease with chemotherapy combinations containing cisplatin and etoposide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Cisplatin, vinblastine, and bleomycin combination therapy in resistant gestational trophoblastic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Cisplatin, vinblastine, and bleomycin combination in the treatment of resistant high-risk gestational trophoblastic tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Ifosfamide alone and in combination in the treatment of refractory malignant gestational trophoblastic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Long-term remission of previously resistant choriocarcinoma with a combination of etoposide, ifosfamide, and cisplatin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

High-Dose Chemotherapy with Autologous Bone Marrow Transplantation for Refractory Metastatic Gestational Trophoblastic Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

In vitro chemosensitivity of paclitaxel and other chemotherapeutic agents in malignant gestational trophoblastic neoplasms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Effects of Taxol on choriocarcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Treatment of resistant gestational choriocarcinoma with taxol: a report of two cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Remission of refractory gestational trophoblastic disease with high-dose paclitaxel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

The role of operation in the current therapy of gestational trophoblastic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Recurrent gestational trophoblastic disease. Experience of the Southeastern Regional Trophoblastic Disease Center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Surgical indications for resection in pulmonary metastasis of choriocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

Prognostic factors in gestational trophoblastic tumors: a proposed new scoring system based on multivariate analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.02.004

10.1016/J.YGYNO.2005.02.004

7 January 2021

Identifiers

DOI

1 reference

12 August 2017

1 reference